SABS (SAB Biotherapeutics) Volatility: 69.38% (As of Jun. 25, 2026)


SABS SAB Biotherapeutics Inc SABS
26 GF Score
Price $3.84
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics Volatility?

SAB Biotherapeutics SABS -1.03% 26 Volatility is 69.38% as of Jun. 25, 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-25), SAB Biotherapeutics's Volatility is 69.38%.

SAB Biotherapeutics  (NAS:SABS) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

SAB Biotherapeutics Volatility Related Terms

SABS vs TRDA, ACIU, AVXL: Volatility Comparison

For the Biotechnology subindustry, SAB Biotherapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SAB Biotherapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where SAB Biotherapeutics's Volatility falls into.


SABS
26GF Score
SAB Biotherapeutics Inc SABS
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SAB Biotherapeutics  (NAS:SABS) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 69.38% mean?
SAB Biotherapeutics (SABS) has a Volatility of 69.38% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on SAB Biotherapeutics and its competitors.
Is SAB Biotherapeutics' Volatility too high?
SAB Biotherapeutics' current Volatility is 69.38%. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' Volatility compare to TRDA and ACIU?
SAB Biotherapeutics' Volatility of 69.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current Volatility is 69.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current Volatility of 69.38%. The current Volatility is 69.38%. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current Volatility is 69.38% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score

Get the complete analysis for SABS

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price